EUVIMEDEUVIMED entdecken
Multizentrische StudieKohortenstudieOpen Access · CC BY-NC 4.0

Outcomes and risk factors for mortality in Pneumocystis pneumonia patients with rheumatoid arthritis: A multicentre retrospective cohort study

Shunsuke Mori iD, Yukitaka Ueki iD, Tomoya Miyamura iD, Koji Ishii iD, Toshihiko Hidaka iD, Tamami Yoshitama iD, Kazuyoshi Nakamura iD, Yasuo Suenaga iD

Modern Rheumatology · 2023

DOI: 10.1093/mr/roac088 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Modern Rheumatology, 2023. Verfasst von Shunsuke Mori und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology, Clinical Research Center for Rheumatic Diseases, National Hospital Organization, Kumamoto Saishun Medical Center, Kohshi,…. Hauptthemen laut MEDLINE: Pneumonia, Pneumocystis, Arthritis, Rheumatoid, Antirheumatic Agents, Lung Diseases, Interstitial. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Hospital Organization.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

The aim is to evaluate outcomes and risk factors for death in patients with rheumatoid arthritis (RA) who developed Pneumocystis pneumonia (PCP).

Methods

We included RA patients who were diagnosed with PCP at seven participating community hospitals between July 2005 and October 2020. Clinical features were compared between survivors and non-survivors. Disease-modifying antirheumatic drugs (DMARDs) before PCP onset and after PCP recovery were also examined.

Results

Seventy RA patients developed PCP, and among them, 60 (85.7%) received methotrexate (MTX) monotherapy (40%) or MTX combination therapy with other DMARDs (45.7%). PCP was more likely to occur after 12 months of MTX monotherapy and within 3 months of MTX combination therapy. Thirteen patients (18.6%) died despite PCP treatment. Multivariable logistic regression analysis revealed that coexisting RA-associated interstitial lung disease (odds ratio, 6.18; 95% confidence interval, 1.17–32.63) and delayed PCP treatment with anti-Pneumocystis drugs (odds ratio, 15.29; 95% confidence interval, 1.50–156.15) are significant risk factors for PCP mortality in RA patients. Most survivors successfully resumed DMARD therapy without PCP prophylaxis; one recurrent PCP case was observed during follow-up (median, 4.1 years).

Conclusions

To avoid a treatment delay, RA patients should be followed up for signs and symptoms of PCP development, especially those with RA-associated interstitial lung disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pneumonia, PneumocystisArthritis, RheumatoidAntirheumatic AgentsLung Diseases, InterstitialHumansRetrospective StudiesMethotrexateRisk Factors

Stichwörter der Autor:innen

Pneumocystis pneumoniaInterstitial lung diseasemethotrexatemortalityrheumatoid arthritis

Substanzen

MethotrexateAntirheumatic Agents

Autor:innen und Institutionen

  • Department of Rheumatology, Clinical Research Center for Rheumatic Diseases, National Hospital Organization, Kumamoto Saishun Medical Center, Kohshi, Kumamoto, Japan.
  • Rheumatic and Collagen Disease Center, Sasebo Chuo Hospital, Sasebo, Nagasaki, Japan.
  • Department of Internal Medicine and Rheumatology, National Hospital Organization, Kyushu Medical Center, Fukuoka, Japan.
  • Department of Rheumatology, Oita Red Cross Hospital, Oita, Japan.
  • Institute of Rheumatology, Miyazaki Zenjinkai Hospital, Miyazaki, Japan.
  • Yoshitama Clinic for Rheumatic Diseases, Kirishima, Kagoshima, Japan.

ORCID-Profile: Shunsuke Mori, Yukitaka Ueki, Tomoya Miyamura, Koji Ishii, Toshihiko Hidaka, Tamami Yoshitama, Kazuyoshi Nakamura, Yasuo Suenaga

Förderung

  • National Hospital Organization

Zitieren

APA

Mori, S., Ueki, Y., Miyamura, T., Ishii, K., Hidaka, T., Yoshitama, T., Nakamura, K., & Suenaga, Y. (2023). Outcomes and risk factors for mortality in Pneumocystis pneumonia patients with rheumatoid arthritis: A multicentre retrospective cohort study. Modern Rheumatology. https://doi.org/10.1093/mr/roac088

Vancouver

Mori S, Ueki Y, Miyamura T, Ishii K, Hidaka T, Yoshitama T, et al. Outcomes and risk factors for mortality in Pneumocystis pneumonia patients with rheumatoid arthritis: A multicentre retrospective cohort study. Modern Rheumatology. 2023. doi:10.1093/mr/roac088

BibTeX
@article{Mori2023,
  author = {Mori, Shunsuke and Ueki, Yukitaka and Miyamura, Tomoya and Ishii, Koji and Hidaka, Toshihiko and Yoshitama, Tamami and Nakamura, Kazuyoshi and Suenaga, Yasuo},
  title = {Outcomes and risk factors for mortality in Pneumocystis pneumonia patients with rheumatoid arthritis: A multicentre retrospective cohort study},
  journal = {Modern Rheumatology},
  year = {2023},
  doi = {10.1093/mr/roac088}
}
Kostenlos starten →